Pliant Therapeutics (NASDAQ:PLRX) Downgraded to Neutral Rating by Citigroup
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) was downgraded by investment analysts at Citigroup from a “buy” rating to a “neutral” rating in a note issued to investors on Monday, Marketbeat Ratings reports. They currently have a $4.00 price objective on the stock, down from their prior price objective of $40.00. Citigroup’s target price would […]
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) was downgraded by investment analysts at Citigroup from a “buy” rating to a “neutral” rating in a note issued to investors on Monday, Marketbeat Ratings reports. They currently have a $4.00 price objective on the stock, down from their prior price objective of $40.00. Citigroup’s target price would […]
